德琪医药-B希维奥成功纳入医保目录
财中社11月28日电德琪医药-B（06996）发布公告，宣布其研发的希维奥®（塞利尼索片）成功纳入2024年版国家医保药品目录，适用于治疗接受过至少两线系统性治疗的复发或难治性弥漫大B细胞淋巴瘤（rrDLBCL）成年患者。该新适应症将于2025年1月1日起正式生效。
希维奥®是全球首款获得批准的核输出蛋白口服选择性XPO1抑制剂，具有新颖的作用机制，并在联合治疗中展现出协同作用。德琪医药致力于在血液及实体肿瘤领域的早期研发和商业化，当前已建立9款临床到商业化各阶段的肿瘤药物产品管线，其中6款具有全球权益，3款具有亚太权益。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10